Lack of activity of amphotericin B in systemic murine fusarial infection.
Systemic fusarial infections have emerged as a significant cause of mortality in cancer patients. Yet, little is known about the management of these infections. The in vivo antifungal activity of amphotericin B in CF1 mice with disseminated fusarial infections was studied. Two pathogenic strains of Fusarium solani were used. Intraperitoneal administration of amphotericin B in daily doses of 0.5, 1, and 2 mg/kg for less than or equal to 10 days did not prolong survival of treated animals. Clearance of F. solani from kidneys was similar in mice treated with 1 mg/kg per day of amphotericin B and in untreated animals. These results are in agreement with the known in vitro and in vivo resistance of Fusarium species to amphotericin B.
Anaissie
E J
EJ
Department of Medical Specialties, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Hachem
R
R
Legrand
C
C
Legenne
P
P
Nelson
P
P
Bodey
G P
GP
D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D004195:Disease Models, Animal; D004361:Drug Tolerance; D005670:Fusarium / Q000187:drug effects*; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D009181:Mycoses / Q000188:drug therapy*
D000666:Amphotericin B